Investment
Features
FeesSafety
Academy
More
Pluang+

XRP Ledger's BatchV1_1 upgrade nears activation with 68.57% validator support, needs 80% for 14 days to launch.

Protocol Fundamentals
08 Sep 2026
Blockonomi
View Source
Neutral
XRP Ledger's BatchV1_1 upgrade nears activation with 68.57% validator support, needs 80% for 14 days to launch.

The XRP Ledger's proposed BatchV1_1 upgrade currently has 68.57% support from validators but requires over 80% approval sustained for 14 consecutive days to activate. This upgrade allows bundling up to eight transactions into one, enabling new use cases like combined token swaps and NFT minting with listing. The original Batch code was pulled due to a security flaw, but BatchV1_1 fixes these issues and has passed an independent audit. Activation could happen by late September if support increases and holds steady, but no date is confirmed yet.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's stock has fallen more than 30%, a rare event seen only a few times in 40 years, mainly due to rising US 10-year Treasury yields making safer investments more attractive compared to McDonald's dividend. Despite the price drop, McDonald's fu...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App